$20MSeries A, 29 January 2026
Funds will commercialize Sepsis ImmunoScore, alongside a separate $20M BARDA contract for pivotal studies.
- Amount
- $20M
- Stage
- Series A
- Announced
- 29 January 2026
- Lead
- PACE Healthcare Capital
- Other investors
- Labcorp Venture Fund, Carle Health
- Use of funds
- Funds will commercialize Sepsis ImmunoScore, alongside a separate $20M BARDA contract for pivotal studies.
- Checked
- Amount and date matched across 2 press sources
- Sources
- Prenosis raises $20M Series A (date approx) hitconsultant.net
Prenosis raises $20M Series A (date approx) startuptalky.com